Results 201 to 210 of about 68,398 (251)

Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus

Indian Journal of Dermatology, Venereology and Leprology, 2006
openaire   +2 more sources

A novel glycosylated anti-CD20 monoclonal antibody from transgenic cattle. [PDF]

Sci Rep, 2018
Zhang R, Tang C, Guo H, Tang B, Hou S, Zhao L, Wang J, Ding F, Zhao J, Wang H, Chen Z, Dai Y, Li N.   +12 more
europepmc   +1 more source

Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant. [PDF]

Am J Transplant, 2019
Redfield RR, Jordan SC, Busque S, Vincenti F, Woodle ES, Desai N, Reed EF, Tremblay S, Zachary AA, Vo AA, Formica R, Schindler T, Tran H, Looney C, Jamois C, Green C, Morimoto A, Rajwanshi R, Schroeder A, Cascino MD, Brunetta P, Borie D.   +21 more
europepmc   +1 more source

Anti-CD20 monoclonal antibodies in membranous nephropathy

Nefrología
Juan Daniel Díaz-García, Avinash Chandu Nanwani, Arturo Villalobos Navarro, Enrique José Antonio Robiou Vivero, Eduardo Guerrero Hinzpeter, Laurence H. Beck Jr, Luis Fernando Quintana   +6 more
openaire   +1 more source

A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. [PDF]

Blood Adv, 2019
Mato AR, Roeker LE, Eyre TA, Nabhan C, Lamanna N, Hill BT, Brander DM, Barr PM, Lansigan F, Cheson BD, Singavi AK, Yazdy MS, Shah NN, Allan JN, Bhavsar EB, Rhodes J, Kennard K, Schuster SJ, Williams AM, Skarbnik AP, Goy AH, Goodfriend JM, Dorsey C, Coombs CC, Tuncer H, Ujjani CS, Jacobs R, Winter AM, Pagel JM, Bailey N, Schuh A, Shadman M, Sitlinger A, Weissbrot H, Muralikrishnan S, Zelenetz A, Kirkwood AA, Fox CP.   +37 more
europepmc   +1 more source

Resolution of Q Fever-Associated Cryoglobulinemia With Anti-CD20 Monoclonal Antibody Treatment. [PDF]

J Investig Med High Impact Case Rep, 2017
Hawkins KL, Janoff EN, Janson RW.
europepmc   +1 more source

Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy. [PDF]

Clin Cancer Res, 2017
Rogers LM, Mott SL, Smith BJ, Link BK, Sahin D, Weiner GJ.   +5 more
europepmc   +1 more source

Receptor-mediated apoptosis in B cells From the regulation of B Cell survival to potential novel approaches for lymphoma therapy [PDF]

Eeva, Jonna
core  

Some of the next articles are maybe not open access.

Related searches:

Ofatumumab, a human anti-CD20 monoclonal antibody

Expert Opinion on Biological Therapy, 2010
Since relapse of chronic lymphocytic leukemia (CLL), and refractoriness to treatment following relapse, is inevitable after initial treatment, development of novel treatment strategies is necessary.CD20 as a therapeutic target for CLL, successes and limitations of current anti-CD20 monoclonal antibody (mAb) therapy, and implications of preclinical and ...
Anders Osterborg
exaly   +3 more sources

IRF8 regulates efficacy of therapeutic anti‐CD20 monoclonal antibodies [PDF]

European Journal of Immunology, 2022
Abstract Anti‐CD20 monoclonal antibodies such as Rituximab, Ofatumumab, and Obinutuzumab are widely used to treat lymphomas and autoimmune diseases. They act by depleting B cells, mainly through Fc‐dependent effectors functions. Some patients develop resistance to treatment but the underlying mechanisms are poorly
Ludivine Grzelak, Ferdinand Roesch, Amaury Vaysse, Anne Biton, Rachel Legendre, Françoise Porrot, Pierre‐Henri Commère, Cyril Planchais, Hugo Mouquet, Marco Vignuzzi, Timothée Bruel, Olivier Schwartz   +11 more
openaire   +5 more sources